

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 20, 2025 (the “**Prospectus**”) issued by Medtide Inc. (泰德醫藥(浙江)股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.

In connection with the Global Offering, Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited act as the Joint Sponsors; and Morgan Stanley Asia Limited and CLSA Limited act as the Sponsor-Overall Coordinators and Overall Coordinators.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Hong Kong Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, June 30, 2025).



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

- Number of Offer Shares under the Global Offering** : 16,800,000 H Shares
- Number of Hong Kong Offer Shares** : 8,400,000 H Shares (as adjusted after reallocation)
- Number of International Offer Shares** : 8,400,000 H Shares (as adjusted after reallocation)
- Offer Price** : HK\$30.60 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and subject to refund)
- Nominal value** : RMB1.00 per H Share
- Stock code** : 3880

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*

Morgan Stanley

 **CITIC SECURITIES**

*Joint Bookrunners and Joint Lead Managers
(in alphabetical order)*

 **光大證券 | 國際**
EVERBRIGHT SECURITIES | INTERNATIONAL

 **發利證券有限公司**
PRIME SECURITIES LIMITED

 **東吳證券(香港)**
SOOCHOW SECURITIES (HONG KONG)

MEDTIDE INC./泰德醫藥(浙江)股份有限公司
ANNOUNCEMENT OF FINAL OFFER PRICE AND
ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 20, 2025 (the “Prospectus”) issued by Medtide Inc. (泰德醫藥(浙江)股份有限公司) (the “Company”).

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information

Stock code	3880
Stock short name	MEDTIDE
Dealings commencement date	June 30, 2025*

* see note at the end of the announcement

Price Information

Final Offer Price	HK\$30.60
Offer Price Range	HK\$28.40 – HK\$30.60

Offer Shares and Share Capital

Number of Offer Shares	16,800,000 H Shares
Number of Offer Shares in Hong Kong Public Offering (as adjusted after reallocation)	8,400,000 H Shares
Number of Offer Shares in International Offering (as adjusted after reallocation)	8,400,000 H Shares
Number of issued Shares upon Listing	141,800,000 Shares

Proceeds

Gross proceeds (Note)	HK\$514.08 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$ (85.31) million
Net proceeds	HK\$428.77 million

Note: Gross proceeds refers to the amount to which the issuer is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	70,338
No. of successful applications	38,685
Subscription level	301.15 times
Claw-back triggered	Yes
No. of Offer Shares initially available under the Hong Kong Public Offering	1,680,000
No. of Offer Shares reallocated from the International Offering	6,720,000
Final no. of Offer Shares under the Hong Kong Public Offering	8,400,000
% of final no. of Offer Shares under the Hong Kong Public Offering to the Global Offering	50%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of places	115
Subscription Level	2.43 times
No. of Offer Shares initially available under the International Offering	15,120,000
No. of Offer Shares reallocated to the Hong Kong Public Offering	6,720,000
Final no. of Offer Shares under the International Offering	8,400,000
% of final no. of Offer Shares under the International Offering to the Global Offering	50%

The Directors confirm that, to the best of their knowledge, information and belief, save for a written consent under paragraph 5(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to a close associate of its existing shareholder¹, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, the Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, the Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

Investor	No. of Offer Shares allocated	% of Offer Shares	% of total issued Shares after the Global Offering	Existing shareholders or their close associates
Dragon Merit Holdings Limited	1,282,500	7.63%	0.90%	No
Welight Capital L.P.	1,282,500	7.63%	0.90%	No
Total	2,565,000	15.27%	1.81%	

Note: For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.

¹ For details, please see “Others/Additional information” in this announcement

Allottee with Consent Obtained

Investor	No. of Offer Shares allocated	% of Offer Shares	% of total issued Shares after the Global Offering	Relationship
<i>Allottee with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Offer Shares by a close associate of an existing Shareholder</i>				
Jingui Yueke (Guangzhou) Private Equity Investment Limited Partnership (金軌粵科(廣州)私募股權投資基金合夥企業(有限合夥)) (“ Jingui Yueke ”)	3,346,300	19.92%	2.36%	Jingui Yueke is a close associate of an existing shareholder of the Company. ^{Note 1}

Notes:

- The Company has applied for, and the Stock Exchange has granted, a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Jingui Yueke, a close associate of an existing shareholder and pre-IPO investor of the Company, Hangzhou Heda New Pharmaceutical Venture Capital Partnership (Limited Partnership) (杭州和達新醫藥創業投資合夥企業(有限合夥)) (“**Hangzhou Heda Xinyiyao**”) to permit the Company to allocate such Offer Shares in the International Offering to Jingui Yueke. The allocation of Offer Shares to Jingui Yueke is in compliance with all the conditions under the consent granted by the Stock Exchange. For details, please refer to the section headed “Others / Additional Information” in this announcement below.
- For details, please refer to the section headed “Others / Additional Information” in this announcement below.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon Listing	Last day subject to the lock-up undertakings ^{Note 1}
Qikang International ^{Notes 1, 2}	59,567,875 (including 11,913,575 H Shares)	16.19%	42.01%	June 29, 2026 ^{Note 3}
Hangzhou Haiding ^{Notes 1, 2}	15,410,125	–	10.87%	June 29, 2026 ^{Note 3}
Ms. Li ^{Notes 1, 2}	10,273,375 (including 5,136,688 H Shares)	6.98%	7.24%	June 29, 2026 ^{Note 3}
Hangzhou Xiyong ^{Notes 1, 2}	5,136,750 (including 5,136,750 H Shares)	6.98%	3.62%	June 29, 2026 ^{Note 3}
Hangzhou Yuanxi ^{Notes 1, 2}	5,136,750 (including 5,136,750 H Shares)	6.98%	3.62%	June 29, 2026 ^{Note 3}
Total	95,524,875	37.13%	67.37%	

Notes:

- Immediately before completion of the Global Offering, Dr. Xu (through Qikang International, an entity controlled by Dr. Xu through her wholly-owned subsidiary Healthy Angel) and Ms. Li (directly and through Hangzhou Haiding, an entity controlled by Ms. Li as to 99% and her spouse, Mr. Li Congyan, as to 1%; and Hangzhou Xiyong and Hangzhou Yuanxi, being partnerships of which Ms. Li is the sole general partner) owned 47.65% and 28.77% of the issued share capital of the Company, respectively, and since the establishment of the Company, Dr. Xu and Ms. Li have been acting in concert with each other and have agreed to continue to act in concert with each other after the Listing, provided that they remain key members in the Group or they remain interested in the share capital of our Company (the “**Concert Party Arrangement**”), together they are collectively entitled to exercise control of approximately 76.42% voting powers of the Company. Immediately following the completion of the Global Offering, Dr. Xu (through Qikang International, an entity controlled by Dr. Xu through her wholly-owned subsidiary Healthy Angel) and Ms. Li (directly and through Hangzhou Haiding, an entity controlled by Ms. Li as to 99% and her spouse, Mr. Li Congyan, as to 1%; and Hangzhou Xiyong and Hangzhou Yuanxi, being partnerships of which Ms. Li is the sole general partner) will hold approximately 67.37% of the enlarged issued share capital of the Company. Accordingly, Dr. Xu, Ms. Li, Qikang International, Healthy Angel, Mr. Li Congyan, Hangzhou Haiding, Hangzhou Xiyong and Hangzhou Yuanxi are a group of Controlling Shareholders and each of them is subject to the same lock-up as disclosed above.
- In view of the Concert Party Arrangement, each of Dr. Xu and Ms. Li is deemed to be interested in the interest of each other under the SFO.
- The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing Shareholders ends on June 29, 2026, being 12 months following the Listing Date.

Cornerstone Investors

Name	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon Listing	Last day subject to the lock-up undertakings ^{Note 1}
Dragon Merit Holdings Limited	1,282,500	1.74%	0.90%	December 29, 2025
Welight Capital L.P.	1,282,500	1.74%	0.90%	December 29, 2025
Total	2,565,000	3.49%	1.81%	

Notes:

- In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December 29, 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.

Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings ^{Note 1}
Lanxi Puhua Shuoyang Xiaying Venture Investment Partnership (Limited Partnership) (蘭溪普華碩陽夏星創業投資合夥企業(有限合夥))	9,131,875 (including 9,131,875 H Shares)	12.41%	6.44%	June 29, 2026
Quzhou Haibang Taida Venture Capital Partnership (Limited Partnership) (衢州海邦肽達創業投資合夥企業(有限合夥))	7,209,375 (including 7,209,375 H Shares)	9.80%	5.08%	June 29, 2026
Hangzhou Heda Xinyiyao ^{Note 2}	5,371,750 (including 5,371,750 H Shares)	7.30%	3.79%	June 29, 2026

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings ^{Note 1}
Shenzhen Minhe Investment Co., Ltd. (深圳市民和投資有限公司)	2,739,625 (including 2,739,625 H Shares)	3.72%	1.93%	June 29, 2026
Hangzhou Haibang Boyuan Venture Capital Partnership (Limited Partnership) (杭州海邦博源創業投資合夥企業(有限合夥))	2,283,000 (including 2,283,000 H Shares)	3.10%	1.61%	June 29, 2026
Hainan Jingsheng Yiqi Private Equity Investment Fund Partnership (Limited Partnership) (海南景盛一期私募股權投資基金合夥企業(有限合夥))	1,369,750 (including 1,369,750 H Shares)	1.86%	0.97%	June 29, 2026
Nanjing Outao Information Technology Co., Ltd. (南京歐陶信息科技有限公可)	1,369,750 (including 1,369,750 H Shares)	1.86%	0.97%	June 29, 2026
Total	29,475,125	40.04%	20.79%	

Notes:

1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
2. The Company has applied for, and the Stock Exchange has granted a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Jingui Yueke, a close associate of an existing shareholder and pre-IPO investor of the Company, Hangzhou Heda Xinyiyao. For details, please refer to the section headed “Others/Additional Information” in this announcement below.

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	3,346,300	39.84%	19.92%	3,346,300	2.36%
Top 5	7,437,700	88.54%	44.27%	7,437,700	5.25%
Top 10	8,389,500	99.88%	49.94%	8,389,500	5.92%
Top 25	8,391,000	99.89%	49.95%	8,391,000	5.92%

Notes

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	27,323,763	37.13%	95,524,875
Top 5	3,346,300	39.84%	19.92%	57,405,688	78.00%	125,606,800
Top 10	6,952,400	82.77%	41.38%	63,751,288	86.62%	131,952,400
Top 25	8,558,700**	101.89%	50.94%	65,357,588	88.80%	133,558,700

Notes

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

** Including H Shares allotted under the Hong Kong Public Offering and International Offering and among which, 169,400 H Shares were allotted under the Hong Kong Public Offering and 8,389,300 H Shares were allotted under the International Offering.

For the purpose of the shareholder concentration analysis, all Shares owned by Hangzhou Heda Xinyiyao and Jingui Yueke are aggregated.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	27,323,763	95,524,875	67.37%
Top 5	3,346,300	39.84%	19.92%	57,405,688	125,606,800	88.58%
Top 10	6,952,400	82.77%	41.38%	63,751,288	131,952,400	93.06%
Top 25	8,558,700**	101.89%	50.94%	65,357,588	133,558,700	94.19%

Note

* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

** *Including H Shares allotted under the Hong Kong Public Offering and International Offering and amongst which, 169,400 H Shares were allotted under the Hong Kong Public Offering and 8,389,300 H Shares were allotted under the International Offering.*

For the purpose of the shareholder concentration analysis, all Shares owned by Hangzhou Heda Xinyiyao and Jingui Yueke are aggregated.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, 70,338 valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
		POOL A	
100	24,499	12,250 out of 24,499 to receive 100 Shares	50.00%
200	5,895	3,006 out of 5,895 to receive 100 Shares	25.50%
300	5,426	2,784 out of 5,426 to receive 100 Shares	17.10%
400	2,251	1,156 out of 2,251 to receive 100 Shares	12.84%
500	2,807	1,443 out of 2,807 to receive 100 Shares	10.28%
600	1,423	732 out of 1,423 to receive 100 Shares	8.57%
700	929	479 out of 929 to receive 100 Shares	7.37%
800	908	469 out of 908 to receive 100 Shares	6.46%
900	452	234 out of 452 to receive 100 Shares	5.75%
1,000	5,390	2,796 out of 5,390 to receive 100 Shares	5.19%
1,500	2,057	1,070 out of 2,057 to receive 100 Shares	3.47%
2,000	2,054	1,073 out of 2,054 to receive 100 Shares	2.61%
2,500	799	419 out of 799 to receive 100 Shares	2.10%
3,000	1,628	859 out of 1,628 to receive 100 Shares	1.76%
3,500	1,026	545 out of 1,026 to receive 100 Shares	1.52%
4,000	798	427 out of 798 to receive 100 Shares	1.34%
4,500	442	238 out of 442 to receive 100 Shares	1.20%
5,000	1,468	798 out of 1,468 to receive 100 Shares	1.09%
6,000	816	448 out of 816 to receive 100 Shares	0.92%
7,000	732	410 out of 732 to receive 100 Shares	0.80%
8,000	614	354 out of 614 to receive 100 Shares	0.72%
9,000	342	200 out of 342 to receive 100 Shares	0.65%

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
10,000	2,730	1,643 out of 2,730 to receive 100 Shares	0.60%
20,000	1,208	100 Shares	0.50%
30,000	725	100 Shares plus 276 out of 725 to receive additional 100 Shares	0.46%
40,000	497	100 Shares plus 318 out of 497 to receive additional 100 Shares	0.41%
50,000	453	200 Shares	0.40%
60,000	242	200 Shares plus 82 out of 242 to receive additional 100 Shares	0.39%
70,000	219	200 Shares plus 145 out of 219 to receive additional 100 Shares	0.38%
80,000	190	300 Shares	0.38%
90,000	102	300 Shares plus 15 out of 102 to receive additional 100 Shares	0.35%
100,000	349	300 Shares plus 140 out of 349 to receive additional 100 Shares	0.34%
150,000	202	500 Shares	0.33%
	<u>69,673</u>	Total number of Pool A successful applicants: 38,020	
POOL B			
200,000	383	4,400 Shares	2.20%
250,000	39	5,300 Shares	2.12%
300,000	54	6,200 Shares	2.07%
350,000	40	7,100 Shares	2.03%
400,000	22	7,900 Shares	1.98%
450,000	15	8,600 Shares	1.91%
500,000	35	9,400 Shares	1.88%
600,000	24	11,200 Shares	1.87%
700,000	11	12,900 Shares	1.84%
840,000	42	15,400 Shares	1.83%
	<u>665</u>	Total number of Pool B successful applicants: 665	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Allocation of Offer Shares to a close associate of an existing Shareholder as placee (with prior written consent under Paragraph 5(2) of the Placing Guidelines)

Jingui Yueke is a close associate of an existing Shareholder of the Company, Hangzhou Heda Xinyiyao.

As of the date of the Prospectus, Hangzhou Heda Xinyiyao held 5,371,750 Shares, representing approximately 4.30% of the total number of issued Shares of the Company prior to the Global Offering. Jingui Yueke has been placed 3,346,300 H Shares at the Offer Price as a placee, representing approximately 19.92% of the total number of Offer Shares available under the Global Offering and approximately 2.36% of the total issued Shares of the Company upon completion of the Global Offering.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to Jingui Yueke. The allocation of Offer Shares to Jingui Yueke is in compliance with all the conditions under the consent granted by the Stock Exchange.

Reallocation

As the Hong Kong Public Offering has been over-subscribed by more than 100 times of the number of the Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedure as disclosed in the paragraph headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and Clawback" in the Prospectus has been applied.

The number of Offer Shares initially available under the Hong Kong Public Offering was 1,680,000 H Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering. As a result of such reallocation, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 8,400,000 H Shares, representing approximately 50% of Offer Shares initially available under the Global Offering.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.

The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 20, 2025 issued by Medtide Inc. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Hong Kong Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, June 30, 2025).*

PUBLIC FLOAT

Immediately after the completion of the Global Offering, an aggregate of 37,143,250 H Shares, representing approximately 26.19% of the issued share capital of the Company will be held in public hands. Therefore, the number of H Shares held in public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08 (1) of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering: (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the H Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, June 30, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting – Hong Kong Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, June 30, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, June 30, 2025 (Hong Kong time). The H Shares will be traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 3880.

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Dr. Xu Qi

*Chairwoman, Executive Director and
Chief Executive Officer*

Hong Kong, June 27, 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Xu Qi (Chairwoman of the board), Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao and Ms. Li Lingmei as executive directors; (ii) Mr. Wu Yihui as non-executive director; and (iii) Dr. Yu Cheung Hoi, Dr. Zhu Xun and Mr. Xia Xinsheng as proposed independent non-executive Directors, effective upon Listing.